CF
FDMT icon

Corebridge Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Corebridge Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,059
Closed -$71.3K – 967
2025
Q1 		$71.3K Sell
22,059
-2,979
-12% -$14K ﹤0.01% 2606
2024
Q4 		$139K Sell
25,038
-1,890
-7% -$14.8K ﹤0.01% 2387
2024
Q3 		$291K Buy
26,928
+120
+0.4% +$1.99K ﹤0.01% 2010
2024
Q2 		$563K Buy
+26,808
New +$673K ﹤0.01% 1629

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's FDMT Position: Q2 2025 in Review

Corebridge Financial sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 22,059 shares — an estimated $71.3K sold.

Corebridge Financial first reported a position in FDMT in Q2 2024 and held it in 4 quarters. The position peaked at $563K in Q2 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

  • Corebridge Financial reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 22,059 4D Molecular Therapeutics shares in Q2 2025, an estimated $71.3K.
  • Corebridge Financial first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's 4D Molecular Therapeutics position peaked at $563K in Q2 2024.
  • 120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.